Short answer
Charles River Laboratories (CRL) filed an 8-K current report with the SEC on February 25, 2026 reporting Item 7.01 (Regulation FD Disclosure). CDMO and Cell Solutions divested to GI Partners primarily for contingent performance-based payments: no meaningful upfront cash, combined 2025 revenue $143M.
Charles River Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- CDMO and Cell Solutions divested to GI Partners primarily for contingent performance-based payments: no meaningful upfront cash, combined 2025 revenue $143M
- European Discovery Services sold to IQVIA for ~$145M cash plus up to $10M contingent; assets generated $144M in 2025 DSA segment revenue
- Divestitures expected to cut 2026 reported revenue by ~5%, shifting guidance to -5.0% to -3.5% reported growth
- Margin positive: transactions projected to add 100+ bps non-GAAP operating margin improvement and ~$0.10 EPS accretion in 2026 partial year
- Updated non-GAAP EPS guidance $10.80–$11.30 vs prior $10.70–$11.20; CDMO deal structure (contingent-only proceeds) is a notable risk vs. clean cash exit
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Charles River Laboratories 8-K filings
Get the next CRL 8-K as it lands
Follow CRL for push alerts, or ask the research agent what this filing means.